Targeting MYC dependence in cancer by inhibiting BET bromodomains

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 40, 2011, Pages 16669-16674

  Mertz, Jennifer A ^a   Conery, Andrew R ^a   Bryant, Barbara M ^a   Sandy, Peter ^a   Balasubramanian, Srividya ^a   Mele, Deanna A ^a   Bergeron, Louise ^a   Sims III, Robert J ^a  

^a Department of Structural Biology   (United States)

Author keywords

BRD2; BRD3; BRD4; JQ1

Indexed keywords

ANTINEOPLASTIC AGENT; JQ1; MYC PROTEIN; NUCLEAR PROTEIN; PROTEIN BET; PROTEIN INHIBITOR; PROTEIN P21; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE ARREST; CELL PROTECTION; CHROMATIN; CHROMOSOME TRANSLOCATION; GENE LOCUS; GENETIC TRANSCRIPTION; GROWTH INHIBITION; LEUKEMIA CELL; LYMPHOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; AZEPINES; BLOTTING, WESTERN; BURKITT LYMPHOMA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED NOD; MICE, SCID; POLYMERASE CHAIN REACTION; PROTEIN STRUCTURE, TERTIARY; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRIAZOLES;

EID: 80053651202     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1108190108     Document Type: Article

References (23)

1. Wu SY, Chiang CM (2007) The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem 282:13141-13145.
2. Sims RJ, 3rd, Belotserkovskaya R, Reinberg D (2004) Elongation by RNA polymerase II: The short and long of it. Genes Dev 18:2437-2468. (Pubitemid 39362887)
3. Yang Z, He N, Zhou Q (2008) Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol Cell Biol 28:967-976. (Pubitemid 351160053)
4. Dey A, Nishiyama A, Karpova T, McNally J, Ozato K (2009) Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription. Mol Biol Cell 20:4899-4909.
5. LeRoy G, Rickards B, Flint SJ (2008) The double bromodomain proteins Brd2 and Brd3 couple histone acetylation to transcription. Mol Cell 30:51-60. (Pubitemid 351470152)
6. Miyoshi S, Ooike S, Iwata K, Hikawa H, Sugaraha K (2009) International Patent No. PCT/JP2008/073864 (WO/2009/084693).
7. Nicodeme E, et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468:1119-1123.
8. Filippakopoulos P, et al. (2010) Selective inhibition of BET bromodomains. Nature 468: 1067-1073.
9. French CA (2010) NUT midline carcinoma. Cancer Genet Cytogenet 203:16-20.
10. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33-40.
11. Shaffer AL, et al. (2008) IRF4 addiction in multiple myeloma. Nature 454:226-231. (Pubitemid 351969894)
12. Dib A, Gabrea A, Glebov OK, Bergsagel PL, KuehlWM (2008) Characterization of MYC translocations in multiple myeloma cell lines. J Natl Cancer Inst Monogr 25-31.
13. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550. (Pubitemid 41528093)
14. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273. (Pubitemid 36792858)
15. Boxer LM, Dang CV (2001) Translocations involving c-myc and c-myc function. Oncogene 20:5595-5610. (Pubitemid 32928100)
16. Herold S, et al. (2002) Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell 10:509-521. (Pubitemid 35284171)
17. Seoane J, Le HV, Massagué J (2002) Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419:729-734. (Pubitemid 35177959)
18. Lapalombella R, et al. (2008) A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res 14:569-578. (Pubitemid 351226127)
19. Vita M, Henriksson M (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16:318-330. (Pubitemid 44311040)
20. Weinstein IB, Joe A (2008) Oncogene addiction. Cancer Res 68:3077-3080, discussion 3080.
21. Wolfer A, et al. (2010) MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci USA 107:3698-3703.
22. Eilers M, Eisenman RN (2008) Myc's broad reach. Genes Dev 22:2755-2766.
23. Albihn A, Johnsen JI, Henriksson MA (2010) MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 107:163-224.